# Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

> **NCT00681330** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tokyo University** · enrollment: 14 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** URC10, TTK, KOC1

## Key facts

- **NCT ID:** NCT00681330
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2009-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681330, "Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00681330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*